Rasmus Søgaard Hansen , Peter H. Nissen , Julie Brogaard Larsen , Mustafa Vakur Bor
{"title":"诊断蛋白质S缺乏症-导航挑战。","authors":"Rasmus Søgaard Hansen , Peter H. Nissen , Julie Brogaard Larsen , Mustafa Vakur Bor","doi":"10.1016/j.clinbiochem.2025.110950","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Describe challenges in diagnosing protein S deficiency.</div></div><div><h3>Methods</h3><div>A women in her late 20 s and pregnant in third trimester (G1P0) suffered non-hemorrhagic adrenal infarction. Thrombophilia testing was performed five months post-partum and included analyses for the factor V Leiden (FVL; NM_000130:c.1601G > A; rs6025) and prothrombin c.20210G > A (NM_000506:c.*97G > A; rs1799963) variants, and measurement of antiphospholipid antibodies, protein C (PC) activity and antigen, protein S (PS) activity and antigen, and antithrombin. Initial testing suggested PS deficiency of unknown type. Therefore, targeted genetic screening of the <em>PROS1</em> gene was performed using Sanger sequencing and multiplex ligation-dependent probe amplification to rule out large structural DNA rearrangements, along with repeated thrombophilia testing.</div></div><div><h3>Results</h3><div>The first round of thrombophilia testing found low PS and PC, and heterozygosity for the FVL variant. FVL is known to falsely reduce PS activity up to 15 %, but not influence antigen assays (free and total PS levels). A <em>PROS1</em> variant was identified (c.698G > A; p.(Arg233Lys)), but as this is relatively common, we classified the variant as likely benign. The final round of thrombophilia testing was performed 8 months after the first, and showed normal PC activity, normal PS total, PS free at the lower normal threshold and low PS activity.</div></div><div><h3>Conclusion</h3><div>The patient does not meet the criteria for PS deficiency based on either coagulation assays or <em>PROS1</em> gene genotyping. This case highlights the necessity for clear guidelines to define the role of <em>PROS1</em> genetic testing in routine clinical practice.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110950"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diagnosing protein S deficiency − Navigating challenges\",\"authors\":\"Rasmus Søgaard Hansen , Peter H. Nissen , Julie Brogaard Larsen , Mustafa Vakur Bor\",\"doi\":\"10.1016/j.clinbiochem.2025.110950\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Describe challenges in diagnosing protein S deficiency.</div></div><div><h3>Methods</h3><div>A women in her late 20 s and pregnant in third trimester (G1P0) suffered non-hemorrhagic adrenal infarction. Thrombophilia testing was performed five months post-partum and included analyses for the factor V Leiden (FVL; NM_000130:c.1601G > A; rs6025) and prothrombin c.20210G > A (NM_000506:c.*97G > A; rs1799963) variants, and measurement of antiphospholipid antibodies, protein C (PC) activity and antigen, protein S (PS) activity and antigen, and antithrombin. Initial testing suggested PS deficiency of unknown type. Therefore, targeted genetic screening of the <em>PROS1</em> gene was performed using Sanger sequencing and multiplex ligation-dependent probe amplification to rule out large structural DNA rearrangements, along with repeated thrombophilia testing.</div></div><div><h3>Results</h3><div>The first round of thrombophilia testing found low PS and PC, and heterozygosity for the FVL variant. FVL is known to falsely reduce PS activity up to 15 %, but not influence antigen assays (free and total PS levels). A <em>PROS1</em> variant was identified (c.698G > A; p.(Arg233Lys)), but as this is relatively common, we classified the variant as likely benign. The final round of thrombophilia testing was performed 8 months after the first, and showed normal PC activity, normal PS total, PS free at the lower normal threshold and low PS activity.</div></div><div><h3>Conclusion</h3><div>The patient does not meet the criteria for PS deficiency based on either coagulation assays or <em>PROS1</em> gene genotyping. This case highlights the necessity for clear guidelines to define the role of <em>PROS1</em> genetic testing in routine clinical practice.</div></div>\",\"PeriodicalId\":10172,\"journal\":{\"name\":\"Clinical biochemistry\",\"volume\":\"138 \",\"pages\":\"Article 110950\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical biochemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009912025000797\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009912025000797","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
Diagnosing protein S deficiency − Navigating challenges
Objective
Describe challenges in diagnosing protein S deficiency.
Methods
A women in her late 20 s and pregnant in third trimester (G1P0) suffered non-hemorrhagic adrenal infarction. Thrombophilia testing was performed five months post-partum and included analyses for the factor V Leiden (FVL; NM_000130:c.1601G > A; rs6025) and prothrombin c.20210G > A (NM_000506:c.*97G > A; rs1799963) variants, and measurement of antiphospholipid antibodies, protein C (PC) activity and antigen, protein S (PS) activity and antigen, and antithrombin. Initial testing suggested PS deficiency of unknown type. Therefore, targeted genetic screening of the PROS1 gene was performed using Sanger sequencing and multiplex ligation-dependent probe amplification to rule out large structural DNA rearrangements, along with repeated thrombophilia testing.
Results
The first round of thrombophilia testing found low PS and PC, and heterozygosity for the FVL variant. FVL is known to falsely reduce PS activity up to 15 %, but not influence antigen assays (free and total PS levels). A PROS1 variant was identified (c.698G > A; p.(Arg233Lys)), but as this is relatively common, we classified the variant as likely benign. The final round of thrombophilia testing was performed 8 months after the first, and showed normal PC activity, normal PS total, PS free at the lower normal threshold and low PS activity.
Conclusion
The patient does not meet the criteria for PS deficiency based on either coagulation assays or PROS1 gene genotyping. This case highlights the necessity for clear guidelines to define the role of PROS1 genetic testing in routine clinical practice.
期刊介绍:
Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.